Innovative Insights into Osteosarcoma: Unraveling the Role of LncRNAs, miRNAs, and CircRNAs in Tumorigenesis and Therapeutic Resistance.
This review summarizes reported roles of miRNAs, lncRNAs, and circRNAs in osteosarcoma tumorigenesis, progression, metastasis, chemoresistance, and their potential use as biomarkers or therapeutic targets.
Open original publication →What the AI sees
This review summarizes reported roles of miRNAs, lncRNAs, and circRNAs in osteosarcoma tumorigenesis, progression, metastasis, chemoresistance, and their potential use as biomarkers or therapeutic targets.
Research significance
The reviewed literature supports associations between non-coding RNA regulation and osteosarcoma biology or treatment resistance; by inference, targeting or measuring selected RNAs could improve treatment selection, overcome chemoresistance, or aid diagnosis and prognosis, but the supplied record provides no validation of a specific intervention or biomarker.
Source abstract
Osteosarcoma (OS) is the most common form of primary bone malignancy, characterized by the production of osteoid tissue and contributing significantly to cancer-related mortality in both pediatric and adult populations. The etiology of OS remains multifactorial, involving genetic predispositions, environmental exposures, and complex molecular alterations. Despite advances in surgery and chemotherapy, therapeutic outcomes remain suboptimal due to the high propensity for metastasis and chemoresistance. This review explores recent insights into the genomic landscape of OS, with a focus on the regulatory roles of microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) in tumor initiation, progression, and therapy resistance. We further examine emerging strategies that target these non-coding RNAs as potential therapeutic agents or biomarkers for diagnosis and prognosis. Ultimately, this review emphasizes the need for innovative RNA-based approaches to improve the clinical management and survival outcomes of osteosarcoma patients.